Previsão

O preço-alvo médio dos analistas é € 33,62 (+19,64%). A mediana é € 33,62 (+19,64%).

Comprar	9
Manter	5
Vender	0

Notícias Ir para o feed de notícias

Immunocore presents KIMMTRAK sales, cash reserve and phase‑III roadmap

Immunocore said at a health conference that KIMMTRAK generated about $220m in H1 2026 (annualized >$400m) and the company has cash and equivalents of $880m; on a quarterly basis it is operating close to breakeven. Management stressed that KIMMTRAK is established as a first‑line standard in key markets, but growth is slowing and first competition is expected within a year. Three phase‑III studies (TEBE‑AM, ADAM, PRISM‑MEL‑301) are expected to deliver important data in the next 2–3 years; additionally, Immunocore is advancing early‑stage programs (Brenetafusp, PRAME, PIWIL1) and a type‑1 diabetes project to validate the platform beyond oncology. » Mais em de.investing.com
Immunocore reports encouraging brenetafusp data in heavily pretreated advanced melanoma

Immunocore reported updated Phase 1/2 results showing brenetafusp monotherapy achieved a 6-month overall survival rate of 87% and a disease control rate of 52% in HLA-A*02:01-positive heavily pretreated melanoma patients. Management said responses and survival were consistent across difficult subgroups, including primary PD-1–resistant patients. The company highlighted confidence in brenetafusp 160 mcg combined with nivolumab in the ongoing Phase 3 PRISM-MEL-301 trial. » Mais em finance.yahoo.com
Jefferies downgrades Immunocore Holdings to hold, sets $33 price target

Jefferies cut Immunocore Holdings from Buy to Hold and lowered its price target to $33 from $48, citing a moderate total addressable market for lead product Kimmtrak and limited near-term upside unless pipeline programs succeed. The firm noted Kimmtrak is nearing peak sales and called additional pipeline shots risky. Immunocore reported Q4 EPS of $(0.60) versus $(0.20) consensus and revenue of $104.5M versus $107.8M, while management highlighted $400M in Kimmtrak sales in 2025 and plans to focus on clinical data and a first autoimmune trial in 2026. » Mais em finance.yahoo.com

Dados financeiros da empresa

No último trimestre, Immunocore Holdings ADS registou receitas de € 101,58 mi e um ganho líquido de -€ 707,98 mil

(EUR)	junho de 2026	YoY
Receitas	101,58 mi	22,21%
Ganho bruto	100,62 mi	22,36%
Ganho líquido	-707,98 mil	91,90%
EBITDA	3,13 mi	157,68%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 1,47 bi
Número de ações	50,83 mi
Máximo/mínimo de 52 semanas	€ 35,10 - € 23,76
Dividendos	Não
Beta	0,74
PER (PE Ratio)	-186,25
PEG (PEG Ratio)	-5,88
P/VC (PB Ratio)	4,08
P/V (PS Ratio)	4,23

Perfil da empresa

Immunocore Holdings plc, ein Biotechnologieunternehmen im kommerziellen Stadium, beschäftigt sich mit der Entwicklung von Immuntherapien zur Behandlung von Krebs, Infektions- und Autoimmunkrankheiten. Das Unternehmen bietet KIMMTRAK für die Behandlung von Patienten mit inoperablem oder metastasiertem Aderhautmelanom an. Die anderen Onkologieprogramme des Unternehmens umfassen IMC-C103C, das sich in einer Phase-I/II-Dosis-Eskalationsstudie bei Patienten mit soliden Tumoren befindet, darunter nicht-kleinzelliger Lungenkrebs (NSCLC), Magenkrebs, Kopf- und Halskrebs, Eierstockkrebs und Synovialsarkom; IMC-F106C, das sich in einer Phase-I/II-Dosis-Eskalationsstudie bei Patienten mit mehreren soliden Tumoren befindet, darunter NSCLC, kleinzelliger Lungenkrebs, Endometriumkrebs, Eierstockkrebs, Hautmelanom und Brustkrebs. Zu den Programmen des Unternehmens zur Behandlung von Infektionskrankheiten gehören IMC-I109V, das sich in einer klinischen Studie der Phase I/II bei Patienten mit chronischer Hepatitis B befindet, und IMC-M113V, das sich in der präklinischen Entwicklungsphase für Patienten mit dem Virus der menschlichen Immunsuppression befindet. Darüber hinaus entwickelt das Unternehmen Produktkandidaten zur gezielten Immunsuppression für die Behandlung von Autoimmunkrankheiten. Immunocore Holdings plc wurde 1999 gegründet und hat seinen Hauptsitz in Abingdon (Vereinigtes Königreich).

Nome	Immunocore Holdings ADS
CEO	Bahija Jallal
Sede	Abingdon, ox Reino Unido
Site	immunocore.com
Setor	Bens de consumo básico
Indústria	Produtos alimentares
Entrada em bolsa	05/02/2021
Colaboradores	524